Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis

Multiple myeloma (MM) is an incurable hematologic malignancy in which patients with relapsed or refractory disease continue to experience poor outcomes despite recent therapeutic advances. The combination of isatuximab, carfilzomib, and dexamethasone (Isa-Kd) demonstrated significant clinical benefit in the phase 3 IKEMA trial; however, real-world evidence remains limited. This multicenter retrospective study evaluated the effectiveness and safety of Isa-Kd in 89 patients with relapsed or refractory MM (RRMM) treated in routine clinical practice. The median age was 61 years, and most patients received Isa-Kd as second-line therapy (77.5%). High-risk clinical features were frequent, including renal impairment, extramedullary disease, refractoriness to lenalidomide (88.6%) and bortezomib (42.7%), and prior exposure to daratumumab. The overall response rate was 83.8%, with 69.8% of patients achieving a very good partial response (VGPR) or better (≥ VGPR). Median progression-free survival (PFS) and overall survival were not reached, while the restricted mean PFS was 23.8 months. Achieving ≥VGPR was independently associated with improved PFS, whereas high-risk clinical features were not significantly associated with inferior PFS. Toxicity was manageable and consistent with previously reported studies. In conclusion, Isa-Kd demonstrated substantial clinical activity and a manageable safety profile in a real-world RRMM population, including patients with adverse clinical characteristics frequently underrepresented in clinical trials. These findings support Isa-Kd as an effective and well-tolerated treatment option in routine clinical practice, including for patient profiles typically excluded from clinical trials.

Authors

Institutions

Publication Details

Journal
Annals of Hematology
Published
2026-11-21
DOI
https://doi.org/10.1007/s00277-026-07369-3
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis

Ester Clavero, M. Carmen Galán, María Casanova, Sebastián Garzón et al.
Annals of Hematology
Multiple Myeloma Research and Treatments
article

Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis

Ester Clavero, M. Carmen Galán, María Casanova, Sebastián Garzón, Ricarda García‐Sánchez, M. Jiménez, Magdalena Alcalá, Isabel García-Cabrera, Rocío Fe, Miguel A. Álvarez
article en

Abstract

Multiple myeloma (MM) is an incurable hematologic malignancy in which patients with relapsed or refractory disease continue to experience poor outcomes despite recent therapeutic advances. The combination of isatuximab, carfilzomib, and dexamethasone (Isa-Kd) demonstrated significant clinical benefit in the phase 3 IKEMA trial; however, real-world evidence remains limited. This multicenter retrospective study evaluated the effectiveness and safety of Isa-Kd in 89 patients with relapsed or refractory MM (RRMM) treated in routine clinical practice. The median age was 61 years, and most patients received Isa-Kd as second-line therapy (77.5%). High-risk clinical features were frequent, including renal impairment, extramedullary disease, refractoriness to lenalidomide (88.6%) and bortezomib (42.7%), and prior exposure to daratumumab. The overall response rate was 83.8%, with 69.8% of patients achieving a very good partial response (VGPR) or better (≥ VGPR). Median progression-free survival (PFS) and overall survival were not reached, while the restricted mean PFS was 23.8 months. Achieving ≥VGPR was independently associated with improved PFS, whereas high-risk clinical features were not significantly associated with inferior PFS. Toxicity was manageable and consistent with previously reported studies. In conclusion, Isa-Kd demonstrated substantial clinical activity and a manageable safety profile in a real-world RRMM population, including patients with adverse clinical characteristics frequently underrepresented in clinical trials. These findings support Isa-Kd as an effective and well-tolerated treatment option in routine clinical practice, including for patient profiles typically excluded from clinical trials.

Annals of Hematology
Hospital Costa del Sol (ES), Hospital Regional Universitario de Málaga (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital Universitario Reina Sofía (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), Hospital Universitario de Jerez (ES)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon